Enlivex Therapeutics announced the issuance of an Israeli patent, numbered 284985, entitled, "Combination Immune Therapy and Cytokine Control Therapy for Cancer Treatment." The patent provides added intellectual property protection in Israel into at least 2037, with claims covering the use of for Allocetra for prevention or amelioration of cytokine storms in cancer patients receiving CAR-T therapy, as well as in patients whose cytokine storms result from infectious diseases or non-infectious sources. Oren Hershkovitz, PhD, CEO of Enlivex commented, "We are pleased with the continued buildup of our comprehensive intellectual property portfolio for Allocetra."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ENLV:
- Enlivex Announces Issuance of Israeli Patent Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome (CRS) Resulting from CAR T-Cell Therapy, Infectious Diseases or Any Non-Infectious Source of CRS
- Enlivex announces recommendation, IMOH clearance for Phase I/II trial
- Enlivex Announces Positive DSMB Recommendation and IMOH Clearance to Continue Phase I/II Trial of Allocetra in Patients with Advanced Solid Tumors
- Enlivex receives authorizations from French, Belgian to expand Sepsis trial